Patents by Inventor Venkata P. Palle
Venkata P. Palle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952380Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: GrantFiled: May 6, 2022Date of Patent: April 9, 2024Assignee: LUPIN LIMITEDInventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20230119316Abstract: Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.Type: ApplicationFiled: December 27, 2020Publication date: April 20, 2023Inventors: Sanjay Pralhad Kurhade, Prathap Sreedharan Nair, Sachin Sethi, Manojkumar Ramprasad Shukla, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj, Samiron Phukan, Pradeep Rangrao Patil, Sayyed Majid, Ramesh Phadatare, Navnath Walke, Vipul Pachpute, Balasaheb Gore, Vikas Tambe, Rohan Limaye, Avadhut Bhosale, Sachin Mahangare
-
Publication number: 20230066014Abstract: The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: ApplicationFiled: December 2, 2020Publication date: March 2, 2023Applicant: Lupin LimitedInventors: Prathap Sreedharan NAIR, Ganesh Bhausaheb GUDADE, Shankar Bhaskar BHAGWAT, Amol Maruti YADAV, Chaitanya Prabhakar KULKARNI, Milind Dattatraya SINDKHEDKAR, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20230013778Abstract: Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, R1 to R5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.Type: ApplicationFiled: November 28, 2020Publication date: January 19, 2023Inventors: Sachin Sethi, Prathap Sreedharan Nair, Manojkumar Ramprasad Shukla, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj, Samiron Phukan, Pradeep Rangrao Patil, Ganesh Kakade, Nilesh Raghunath Khedkar, Dagadu Dube, Vikas Sitaram Tambe, Sudhakar Maruti Balgude, Pradip Balu Wagh
-
Publication number: 20220395508Abstract: This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided are pharmaceutical combination comprising a PRMT5 Inhibitor and a cellular activity modulator selected from an EGFR inhibitor, a KRAS inhibitor, a KRAS-G12C inhibitor, a MEK inhibitor, a Bcl-2 inhibitor, a SOS1 inhibitor, a PARP inhibitor, a RAF inhibitor, a ERK inhibitor, a CDK4/6 inhibitor, a MALT1 inhibitor, a BTK inhibitor, MAT2A inhibitor, a PI3K inhibitor, a AKT inhibitor, a FGFR inhibitor, a Type I PRMT inhibitor, a STING agonist, or an immune checkpoint inhibitor/modulator.Type: ApplicationFiled: October 22, 2020Publication date: December 15, 2022Inventors: Mandar Ramesh Bhonde, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20220315589Abstract: The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: ApplicationFiled: June 9, 2020Publication date: October 6, 2022Inventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Mahadeo Bhaskar Tryambake, Chetan Sanjay Pawar, Dipak Raychand Lagad, Chaitanya Prabhakar Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 11459330Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: GrantFiled: December 13, 2018Date of Patent: October 4, 2022Assignee: LUPIN LIMITEDInventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20220289763Abstract: Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.Type: ApplicationFiled: July 22, 2020Publication date: September 15, 2022Inventors: Navnath Popat Karche, Moloy Banerjee, Nishant Ramnivasji Gupta, Ganesh Rajaram Jadhav, Vinod Popatrao Vyavahare, Amit Kumar Das, Deepak Sahebrao Walke, Vaibhav Madhukar Kalhapure, Smita Aditya Bhoskar, Vidya Ramdas, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20220267339Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: ApplicationFiled: May 6, 2022Publication date: August 25, 2022Applicant: LUPIN LIMITEDInventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20220144852Abstract: Disclosed are the macrocyclic compounds having the general Formula (I) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.Type: ApplicationFiled: March 21, 2020Publication date: May 12, 2022Applicant: LUPIN LIMITEDInventors: Navnath Popat KARCHE, Moloy BANERJEE, Pradeep Rangrao PATIL, Vinod Popatrao VYAVAHARE, Deepak Sahebrao WALKE, Vaibhav Madhukar KALHAPURE, Vidya RAMDAS, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20210163486Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.Type: ApplicationFiled: December 13, 2018Publication date: June 3, 2021Applicant: LUPIN LIMITEDInventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20210052556Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.Type: ApplicationFiled: March 26, 2020Publication date: February 25, 2021Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20200101068Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.Type: ApplicationFiled: August 13, 2016Publication date: April 2, 2020Applicant: Lupin LimitedInventors: Navnath Popat Karche, Ajay Ramchandra Tilekar, Sanjay Pralhad Kurhade, Ganesh Rajaram Jadhav, Nishant Ramniwasji Gupta, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20190275012Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.Type: ApplicationFiled: July 28, 2017Publication date: September 12, 2019Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20190160045Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.Type: ApplicationFiled: July 28, 2017Publication date: May 30, 2019Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 10292981Abstract: The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).Type: GrantFiled: July 6, 2017Date of Patent: May 21, 2019Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 10239869Abstract: The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.Type: GrantFiled: September 3, 2016Date of Patent: March 26, 2019Assignee: LUPIN LIMITEDInventors: Vidya Ramdas, Rajeshkumar Maganlal Loriya, Moloy Banerjee, Pradeep Rangrao Patil, Advait Arun Joshi, Laxmikant Shamlal Datrange, Deepak Sahebrao Walke, Talha Hussain Khan, Amit Kumar Das, Ganesh Navinchandra Gote, Vaibhav Madhukar Kalhapure, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20180186777Abstract: The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.Type: ApplicationFiled: September 3, 2016Publication date: July 5, 2018Inventors: Vidya RAMDAS, Rajeshkumar Maganlal LORIYA, Moloy BANERJEE, Pradeep Rangrao PATIL, Advait Arun JOSHI, Laxmikant Shamlal DATRANGE, Deepak Sahebrao WALKE, Talha Hussain KHAN, Amit Kumar DAS, Ganesh Navinchandra GOTE, Vaibhav Madhukar KALHAPURE, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Patent number: 9987249Abstract: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.Type: GrantFiled: January 26, 2017Date of Patent: June 5, 2018Assignee: LUPIN LIMITEDInventors: Manojkumar Ramprasad Shukla, Ankush Gangaram Sarde, Rajeshkumar Maganlal Loriya, Vipul Dilip Pachpute, Navnath Bajirao Walke, Talha Hussain Khan, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: RE47351Abstract: N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.Type: GrantFiled: June 27, 2017Date of Patent: April 16, 2019Assignee: Gilead Sciences, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli